Cargando…

GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine

Multivalent tetanus and diphtheria toxoid containing vaccines belong to the most frequently applied vaccines. However, there is an imbalance in the degree of protection against the two antigens with insufficient long-term protection against diphtheria, particularly in the elderly population. We have...

Descripción completa

Detalles Bibliográficos
Autores principales: Grasse, Marco, Meryk, Andreas, Miggitsch, Carina, Grubeck-Loebenstein, Beatrix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116485/
https://www.ncbi.nlm.nih.gov/pubmed/29961602
http://dx.doi.org/10.1016/j.vaccine.2018.06.033
_version_ 1783514222388314112
author Grasse, Marco
Meryk, Andreas
Miggitsch, Carina
Grubeck-Loebenstein, Beatrix
author_facet Grasse, Marco
Meryk, Andreas
Miggitsch, Carina
Grubeck-Loebenstein, Beatrix
author_sort Grasse, Marco
collection PubMed
description Multivalent tetanus and diphtheria toxoid containing vaccines belong to the most frequently applied vaccines. However, there is an imbalance in the degree of protection against the two antigens with insufficient long-term protection against diphtheria, particularly in the elderly population. We have previously reported a positive correlation between granulocyte macrophage-colony stimulating factor (GM-CSF) and the production of diphtheria-specific antibodies. Therefore, in the present study we analyzed the effects of in vivo applied recombinant GM-CSF on immunization with multivalent tetanus/diphtheria vaccine in mice of different age. In vivo application of GM-CSF lead to enhanced production of diphtheria-specific antibodies as well as more diphtheria-specific CD4(+) T cells following vaccination with multivalent tetanus/diphtheria vaccine. In contrast, the humoral and cellular immune response to the tetanus component was unaltered. Furthermore, application of GM-CSF resulted in more splenic CD11b(+) dendritic cells (DCs) with a higher MHC-II expression. GM-CSF also induced a stronger recruitment of CD11b(+) DCs to the injected muscle. Most remarkably, GM-CSF was able to boost the diphtheria-specific immune response to the multivalent vaccine in aged mice. This study demonstrates that local administration of GM-CSF is able to improve immune responsiveness to the diphtheria component of multivalent tetanus/ diphtheria vaccine in young and old mice. This information could be useful for the future design of vaccines for the elderly.
format Online
Article
Text
id pubmed-7116485
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-71164852020-12-18 GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine Grasse, Marco Meryk, Andreas Miggitsch, Carina Grubeck-Loebenstein, Beatrix Vaccine Article Multivalent tetanus and diphtheria toxoid containing vaccines belong to the most frequently applied vaccines. However, there is an imbalance in the degree of protection against the two antigens with insufficient long-term protection against diphtheria, particularly in the elderly population. We have previously reported a positive correlation between granulocyte macrophage-colony stimulating factor (GM-CSF) and the production of diphtheria-specific antibodies. Therefore, in the present study we analyzed the effects of in vivo applied recombinant GM-CSF on immunization with multivalent tetanus/diphtheria vaccine in mice of different age. In vivo application of GM-CSF lead to enhanced production of diphtheria-specific antibodies as well as more diphtheria-specific CD4(+) T cells following vaccination with multivalent tetanus/diphtheria vaccine. In contrast, the humoral and cellular immune response to the tetanus component was unaltered. Furthermore, application of GM-CSF resulted in more splenic CD11b(+) dendritic cells (DCs) with a higher MHC-II expression. GM-CSF also induced a stronger recruitment of CD11b(+) DCs to the injected muscle. Most remarkably, GM-CSF was able to boost the diphtheria-specific immune response to the multivalent vaccine in aged mice. This study demonstrates that local administration of GM-CSF is able to improve immune responsiveness to the diphtheria component of multivalent tetanus/ diphtheria vaccine in young and old mice. This information could be useful for the future design of vaccines for the elderly. 2018-07-25 2018-06-28 /pmc/articles/PMC7116485/ /pubmed/29961602 http://dx.doi.org/10.1016/j.vaccine.2018.06.033 Text en http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Grasse, Marco
Meryk, Andreas
Miggitsch, Carina
Grubeck-Loebenstein, Beatrix
GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine
title GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine
title_full GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine
title_fullStr GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine
title_full_unstemmed GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine
title_short GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine
title_sort gm-csf improves the immune response to the diphtheria-component in a multivalent vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116485/
https://www.ncbi.nlm.nih.gov/pubmed/29961602
http://dx.doi.org/10.1016/j.vaccine.2018.06.033
work_keys_str_mv AT grassemarco gmcsfimprovestheimmuneresponsetothediphtheriacomponentinamultivalentvaccine
AT merykandreas gmcsfimprovestheimmuneresponsetothediphtheriacomponentinamultivalentvaccine
AT miggitschcarina gmcsfimprovestheimmuneresponsetothediphtheriacomponentinamultivalentvaccine
AT grubeckloebensteinbeatrix gmcsfimprovestheimmuneresponsetothediphtheriacomponentinamultivalentvaccine